Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. September 2016 08:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

HOUSTON, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
10. August 2016 07:30 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Reports Second Quarter 2016 Financial Results

HOUSTON, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
03. August 2016 08:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings to Announce Second Quarter 2016 Financial Results on August 10, 2016

HOUSTON, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
06. Juli 2016 08:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference

HOUSTON, July 06, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
29. Juni 2016 11:58 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering

HOUSTON, June 29, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense...
28. Juni 2016 08:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer

HOUSTON, June 28, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
20. Juni 2016 16:01 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings to Join Russell 3000® and Global Indexes

HOUSTON, June 20, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
06. Juni 2016 09:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016

HOUSTON, June 06, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
19. Mai 2016 07:30 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting

HOUSTON, May 19, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
11. Mai 2016 07:30 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Reports First Quarter 2016 Financial Results

HOUSTON, May 11, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...

Vorherige Seite